Kratom Treatment Admissions Surge 525% at California Center as Federal Policy Scrutiny Deepens

Why it matters

A 525% jump in kratom-related treatment admissions at a single California facility in just five months of 2026 signals an accelerating clinical crisis — while simultaneous reporting on political entanglements raises questions about the integrity of federal oversight.

The big picture

Kratom has moved from a niche supplement to a mainstream public health concern, with poison control calls up 1,200% over a decade and now treatment centers documenting exponential admission increases. At the same time, The New York Times published an investigation revealing ties between HHS Secretary Robert F. Kennedy Jr., kratom industry executive Aaron Ross, and Botanic Tonics — a company previously sued by the federal government — raising concerns about political influence on regulatory decisions.

Key findings

• Laguna Treatment Center in Aliso Viejo, CA, reported 25 kratom dependence admissions in the first 5 months of 2026 — a 525% increase compared to 4 admissions for all of 2025
• Kratom was found in the systems of more than 5,200 people who died from drug overdoses between 2020 and 2024, per CDC data
• More than 5 million Americans have used kratom in their lifetimes, including over 100,000 children ages 12-17
• NYT investigation found kratom industry executive Aaron Ross increased donations to RFK Jr.s presidential campaign after Trump selected Kennedy as HHS secretary
• The FDA reportedly removed links about a pending legal case against Botanic Tonics after allies of Ross pushed for the change; DOJ later dropped the lawsuit
• RFK Jr. called Ohios governor in fall 2025 to oppose a state kratom ban; Botanic Tonics later donated $1 million to a Kennedy-affiliated PAC

What they say

The New York Times investigation, based on campaign finance data, lobbying disclosures, court filings, and interviews, documented that kratom industry lobbyists secured a private meeting with Vice President JD Vance "where they discussed kratom and urged a ban on synthetic products."

Bottom line

**Kratom treatment admissions are skyrocketing at clinical facilities while a New York Times investigation raises serious questions about whether political relationships are shaping federal regulatory decisions on the substance.**